MedTrace Logo

Different Ozone Concentrations for Knee Osteoarthritis

NCT07662512 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2026-06-23

No results posted yet for this study

Summary

Knee osteoarthritis is a common condition that causes pain, stiffness, and difficulty with daily activities. Ozone injection therapy is a minimally invasive treatment that has been increasingly used to relieve symptoms in people with knee osteoarthritis. However, it is not clear whether different ozone concentrations produce different treatment outcomes.

In this study, we compared the effects of two commonly used ozone concentrations (15 μg/mL and 25 μg/mL) in patients with knee osteoarthritis. A total of 159 patients received intra-articular ozone injections and were followed for 3 months. Pain, physical function, and quality of life were assessed before treatment and at 1 and 3 months after the injections.

Conditions

  • Knee Osteoarthristis
  • Gonarthrosis

Interventions

OTHER

ozone injection

Ozone (O2-O3) therapy is widely used in clinical practice as an alternative medical approach in the treatment of musculoskeletal diseases. Many recent studies have reported that intra-articular ozone implementation has a positive impact on knee osteoarthritis. Most available studies have focused on the comparison of ozone therapy with other intra-articular injections. However, the influence of the concentration and/or volume of the ozone used during injection on treatment outcomes has been omitted. The concentration of ozone administered into the joint varies, typically ranging from 15 to 30 μg/ml in these studies; however, there is no consensus regarding the appropriate dosage to be used. Based on this gap in the literature, we aimed to compare pain, functional status and quality of life among patients treated with different concentrations of intra-articular ozone therapy.

Sponsors & Collaborators

  • Sakarya University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2024-05-02
Completion
2024-06-03

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07662512 on ClinicalTrials.gov